Gannet BioChem

Gannet BioChem Is Officially SBTi-Validated! We’re proud to announce that Science Based Targets initiative (SBTi) has validated our near-term greenhouse gas reduction targets, underscoring our commitment to sustainable, science-driven growth across polymer chemistry and CDMO services. 🔹 63% reduction in Scope 1 & 2 GHG emissions by 2035 (2020 baseline) 🔹 Commitment to measure and reduce Scope 3 emissions across our value chain This milestone reflects our dedication to environmental responsibility while continuing to support next-generation therapeutics. Learn more in the full release: 👉 https://lnkd.in/gkbpyiJW #Sustainability #ClimateAction #CDMO #Biopharma #LifeSciences #GannetBioChem

We recently received thoughtful feedback from a Chief R&D Officer in the biopharmaceutical industry who has partnered with our Huntsville team for more than a decade. They shared how our scientists and engineers have supported their pipeline by delivering high-quality PEG conjugates for clinical supply, including a program that is now advancing toward Phase 3 and commercial scale. We appreciate the trust our partners place in us and are proud of the meaningful work happening at Gannet BioChem every day. To learn more about our PEG capabilities and how we support programs from early development through scale-up, visit gannetbiochem.com. #Biopharma #DrugDevelopment #PEGylation #PolymerChemistry #ClinicalDevelopment #Bioconjugation #CDMO

Get the latest jobs and industry news

Advancing innovative drug delivery through strategic collaboration. Gannet BioChem is pleased to announce a development and cGMP supply agreement with Re-Vana Therapeutics to support the advancement of its proprietary biodegradable polymer platforms for sustained-release drug delivery. By combining Re-Vana’s innovative ophthalmic technologies with Gannet’s expertise in polymer chemistry, process development, and cGMP manufacturing, this collaboration aims to support next-generation therapies designed to reduce treatment burden and improve patient outcomes. The agreement will support Re-Vana’s EyeLief® and OcuLief® platforms, as well as emerging non-ocular applications. We're excited to take this next step together! Read the full announcement: https://lnkd.in/ef4Pbmyg #GannetBioChem #ReVanaTherapeutics #DrugDelivery #Biotechnology #cGMP #Ophthalmology

Our sustainability goals are taking shape at Gannet BioChem. Through TVA EnergyRight’s Strategic Energy Management program, we’re finding practical ways to use less energy at our Huntsville facility. An air-leak survey and air-compressor replacement are complete, with additional efficiency projects underway. This work supports our SBTi-validated goal to reduce Scope 1 and 2 emissions by 63% by 2035 from a 2020 baseline. We’re grateful to the TVA EnergyRight team for helping us turn that commitment into action. Read the announcement: https://lnkd.in/e3f4B4aA #Sustainability #Biopharma #EnergyEfficiency

At Gannet BioChem, we believe the best innovations happen through strong partnerships. We’re proud to announce our development partnership with Serina Therapeutics, Inc. to support the advancement of SER-252, an investigational therapy for advanced Parkinson’s disease. Together, we’re helping accelerate the development of promising therapies through Gannet’s expertise in process development, scale-up, and manufacturing. Read the full announcement here: https://lnkd.in/eMNKV_Kt #GannetBioChem #CDMO #Biotechnology #DrugDevelopment #ParkinsonsDisease #LifeSciences #Innovation